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ABSTRACT
Background: In this brief report, we discuss enhancing access to hepatitis C treatment for uninsured patients in Southeast
Georgia.
Methods: Through our screening program for hepatitis C virus (HCV) infections in a local safety net emergency department, the
Comprehensive AIDS Resources Emergency (CARE) Initiative studied the rates of linkage to care for newly diagnosed patients
with HCV and sought ways to improve linkage to care for those who did not have health insurance.
Results: Our multidisciplinary team partnered with a local federally qualified health center (FQHC) and a wholesale laboratory
service to offer affordable care options, thus increasing the percent of uninsured patients who were linked to care for the treatment
of their chronic HCV infections.
Conclusions: The creative use of non-invasive laboratory testing from non-traditional sources, and collaboration with
pre-existing community partners is one way to make the care of chronic HCV infection attainable by uninsured and underinsured
patients
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INTRODUCTION
The Centers for Disease Control and Prevention (CDC),
American Association for the Study of Liver Diseases
(AASLD), and Infectious Diseases Society of America
(IDSA) all recommend hepatitis C virus (HCV) screening at
least once for individuals aged 18 and older (Schillie et al.,
2020; AASLD and IDSA, 2019). A recent U.S. Preventive
Services Task Force (USPSTF) update similarly
recommends HCV testing for adults aged 18 to 79 (Chou et
al., USPSTF 2019). This brief report describes how one of
the Comprehensive AIDS Resources Emergency (CARE)
Initiative’s screening programs enhanced access to care for
uninsured patients who test positive for HCV.
METHODS
The data from this brief report come from the CARE
Initiative (Okafor, 2019), a grant-funded screening program
housed in the emergency department (ED) of a safety net
hospital in the Savannah-Chatham County area. Safety net
hospitals, as defined by the Institute of Medicine, commit to
providing care to a substantial share of vulnerable patients
regardless of their ability to pay (Popescu et al, 2019).

Based on the most recent national data, Georgia had the
sixth highest number of newly reported cases of confirmed
chronic hepatitis C out of all states reporting data in 2017
(CDC, 2019).
The CARE Initiative’s HCV screening program began in
February 2017, providing opt-out testing for ED patients
born between 1945-1965 who were not previously tested;
this was per the previous CDC guidelines (Chou et al.,
2013) that recommended one-time testing only for adults
born in this birth cohort and for at-risk individuals. Based on
emerging evidence and the updated AASLD, IDSA, and
USPSTF guidelines, we extended our screening program to
include all adults aged 18 and older in March 2019. The
initial screen is an HCV antibody test; positive antibody
tests are followed by a confirmatory viral load test.
Confirmed positive patients are counseled on the diagnosis
by CARE linkage specialists and then linked to community
providers. These linkage specialists continue with follow-up
phone contact until an outpatient provider assumes care of
the patient’s HCV infection.

We obtained Institutional Review Board approval to study
the demographics of all patients screened for HCV through
the ED to implement quality improvement and
population-level interventions to decrease the burden of
HCV infection in the community. We measured the percent
of patients who were successfully linked to care for the
management of their HCV infection and studied linkage
rates for various demographic variables, including insurance
status.
RESULTS
Prior to the expansion of the program, approximately 5,000
HCV tests were performed annually in the ED; once
screening moved beyond the birth cohort to include all
adults, we screened more than 15,000 patients in the
subsequent year. The percentage of screened patients who
tested positive (2.7%) did not change significantly after the
age inclusion criteria moved beyond the 1945-1965 birth
cohort; this is likely related to the fact that many older
patients returned to the ED for various medical reasons after
their one-time HCV test, and they were no longer eligible
for screening. The linkage rate for all patients was 39% for
the year leading up to the expansion beyond the birth cohort,
and 36% in the subsequent year.
Approximately 21% of those screened for HCV in the ED
were uninsured or “self-pay” patients, and we discovered
significant difficulty in linking these patients to care
compared to our insured patients. A physician member of
the CARE Initiative also worked part-time at a local
federally qualified health center (FQHC) that cares for
uninsured patients, and they agreed to see patients with
HCV there. The CARE Initiative covers the cost of the HCV
tests for diagnosis and confirmation; however, FQHC
administrators had concerns about their ability to cover the
more than $1,000 per patient cost of the subsequent lab
testing—specifically the HCV genotype test [for the specific
strain of the virus] and tests for liver cirrhosis—that are
required for management after the initial diagnosis. Through
online searches for wholesale laboratory services, the CARE
program coordinator found a partner in January 2020 that
provided an adjusted price of $300 for the subsequent labs.
Nine uninsured patients have already been successfully
linked as of the time of submission; considering our average
of 85 uninsured new diagnoses annually, this trend is
significant. In our city, there were previously no providers
who would accept uninsured patients for management of
hepatitis C, creating a significant health inequity. Our
interdisciplinary team of physicians, linkage specialists,
laboratory technicians, and clinic administrators created a
partnership that can be replicated to provide care for these
patients.

DISCUSSION/CONCLUSIONS
Previous
initiatives
have
demonstrated
the
cost-effectiveness and impact of large-scale screening
programs for HCV in emergency departments and primary
care settings (Assoumou et al, 2018; Hsieh et al., 2016). The
management of our patients after diagnosis was highly
variable and impacted by differences in insurance status and
reimbursement. A wholesale lab company based in a
different state provided affordable prices for the tests
required to manage and care for our newly diagnosed,
uninsured patients with HCV. The lab service interfaces
with multiple vendors and couriers that the FQHC uses for
processing of results, which is how we obtained the lowest
possible price.
Prior to our use of the wholesale laboratory service, we
found only two providers in the county that would accept
our uninsured patients diagnosed with HCV. Because of
heavy patient loads for non-HCV related issues, one of these
providers agreed to accept a maximum of two patients per
month, and they had strict eligibility criteria for accepting
patients with HCV—including complete sobriety from
alcohol and current management of any psychiatric
diagnoses. For uninsured patients that were eligible, the
monthly maximum created a long wait-list.
When we approached other providers in our area about
managing uninsured patients with HCV at perhaps a
reduced rate with upfront cash payments, we encountered
non-financial barriers as well. One clinic mentioned the
downsides of targeting “that patient population” and had
concerns about becoming known as “the Hep C Clinic.” The
FQHC that we ultimately partnered with is accustomed to
caring for individuals of any income level and insurance
status, as well as patients with psychiatric or substance
abuse disorders. We found several uninsured patients
willing to pay the adjusted wholesale price of $300, and in
April 2020 we were able to decrease this cost further to
$180 for most patients. Since the initial implementation has
been cost neutral for the FQHC, they are exploring the
development of additional HCV screening and management
programs for some of their other community partners.
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Disclaimer
The CARE Initiative is funded by a FOCUS (Frontlines of
Communities in the United States) grant through Gilead
Sciences, Inc. FOCUS limits its support to testing and
linkage to care. FOCUS does not support treatment and
remains agnostic in partners' treatment decisions.
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